Home » Newsletters » BioWorld Science

BioWorld Science

July 16, 2015

View Archived Issues

Dendritic cell vaccination induces tumor-specific immune responses

China Food and Drug Administration accepts clinical trial application for sirotinib

ONO-7750512 shows potent antithrombotic effect without increasing bleeding risk

Bristol-Myers Squibb provides update on pipeline for fibrotic diseases

Aerpio Therapeutics reports data from phase IIa study of AKB-9778 in DME

CytoDyn reports evidence of HIV suppression with PRO-140

Pharmacological profile a novel FXIa inhibitor from Sumitomo Dainippon presented

Initiation of phase II study of Ad26.ZEBOV and MVA-BN-Filo Ebola prime-boost vaccine regimen

Esteve discloses sigma1-receptor ligands

Wee1-like protein kinase inhibitors in early development at Almac Discovery

A*STAR patent describes Wnt signaling inhibitors

BTK inhibitors described in Merck & Co. patent

IRM divulges antiparasitic agents

Santen launches Ikervis in Germany for keratitis in dry eye disease

FDA grants orphan drug designation to DPX-Survivac for ovarian cancer

ValiRx announces plans for phase II trial of VAL-401

Treeway and collaborators receive grant to develop edaravone for ALS

Nanocarrier formulation improves delivery of CsA to the eye

FDA gives orphan drug designation to Kevetrin for ovarian cancer

AB Science initiates phase II/III trial of masitinib in ovarian cancer

Cerenis releases results from LOCATION study of CER-001 in atherosclerotic disease

AstraZeneca enters into commercialization option agreement for benralizumab in Japan

Celgene to acquire Receptos

ErepoXen increases hemoglobin levels to therapeutic range in phase II trial

Swedish Orphan Biovitrum exercises Alprolix opt-in right

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...